Condensed Consolidated Statements of Operations and Comprehensive Loss - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		9 Months Ended
	Sep. 30, 2017	Sep. 30, 2016	Sep. 30, 2017	Sep. 30, 2016
Income Statement [Abstract]
Revenue	$ 45,986	$ 52,122	$ 137,154	$ 145,462
Cost of goods sold	16,879	15,191	47,181	51,131
Gross profit	29,107	36,931	89,973	94,331
Operating expenses:
Research and development	5,277	8,236	16,541	23,796
Clinical and regulatory affairs	3,211	3,759	9,786	11,664
Marketing and sales	21,536	26,007	71,217	82,749
General and administrative	8,332	9,714	25,109	29,869
Restructuring costs	98	498	235	8,612
Settlement costs	0	0	0	4,650
Contract termination and business acquisition expenses	0	(49)	0	5,856
Total operating expenses	38,454	48,165	122,888	167,196
Loss from operations	(9,347)	(11,234)	(32,915)	(72,865)
Other income (expense):
Interest income	8	58	80	168
Interest expense	(6,021)	(4,084)	(16,119)	(11,681)
Other income (expense), net	349	189	525	(723)
Change in fair value of contingent consideration related to acquisition	800	0	3,400	(100)
Loss on debt extinguishment	0	0	(6,512)	0
Change in fair value of derivative liabilities	0	0	0	(43,831)
Total other income (expense)	(4,864)	(3,837)	(18,626)	(56,167)
Net loss before income tax expense	(14,211)	(15,071)	(51,541)	(129,032)
Income tax expense	(62)	(174)	(338)	(720)
Net loss	(14,273)	(15,245)	(51,879)	(129,752)
Other comprehensive income (loss) foreign currency translation	232	153	1,369	1,067
Comprehensive loss	$ (14,041)	$ (15,092)	$ (50,510)	$ (128,685)
Basic and diluted net loss per share (in dollars per share)	$ (0.17)	$ (0.18)	$ (0.62)	$ (1.61)
Shares used in computing basic and diluted net loss per share (in shares)	83,496	82,446	83,225	80,402